UBS Genomics 2.0 and Medtech Innovations Virtual Summit Webcast Link https://event.webcasts.com/starthere.jsp?ei=1353253&tp_key=df532808f4
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology https://archerdx.com/invitae-and-archerdx-to-create-a-global-leader-in-comprehensive-cancer-genetics-and-precision-oncology/

Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology — Combination to bring germline and somatic testing, liquid biopsy […]
ArcherDX Enters Collaboration with Bristol Myers Squibb to Apply Personalized Cancer Monitoring (PCM™) to Clinical Research https://archerdx.com/archerdx-enters-collaboration-with-bristol-myers-squibb-to-apply-personalized-cancer-monitoring-pcm-to-clinical-research/

ArcherDX Enters Collaboration with Bristol Myers Squibb to Apply Personalized Cancer Monitoring (PCM™) to Clinical Research Aims to Inform use of Minimal Residual Disease (MRD) […]
ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD) https://archerdx.com/archerdx-announces-strategic-collaboration-with-astrazeneca-to-develop-personalized-cancer-monitoring-pcm-assays-for-minimal-residual-disease-mrd/

ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD) AstraZeneca to Leverage ArcherDX’s PCM Liquid Biopsy […]
ArcherDX Receives Breakthrough Device Designation to Detect NTRK Gene Fusions https://archerdx.com/archerdx-receives-breakthrough-device-designation-to-detect-ntrk-gene-fusions/

ArcherDX Receives Breakthrough Device Designation to Detect NTRK Gene Fusions BOULDER, Colo., May 19, 2020 /PRNewswire/ — ArcherDX, Inc. today announced that the U.S. Food […]
Bayer and ArcherDX Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) for VITRAKVI® (larotrectinib) https://archerdx.com/bayer-and-archerdx-announce-global-collaboration-to-develop-next-generation-sequencing-ngs-based-companion-diagnostic-cdx-for-vitrakvi-larotrectinib/

Bayer and ArcherDX Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) for VITRAKVI® (larotrectinib) Collaboration will focus on development of a companion […]
ArcherDX Appoints Jason Ryan to Board of Directors https://archerdx.com/archerdx-appoints-jason-ryan-to-board-of-directors/

ArcherDX Appoints Jason Ryan to Board of Directors BOULDER, Colo., May 7, 2020 /PRNewswire/ — ArcherDX, Inc. today announced the appointment of Jason Ryan, Chief […]
ArcherDX and UCL Present New Minimal Residual Disease Surveillance Data from their Collaboration at 2020 AACR Virtual Annual Meeting https://archerdx.com/archerdx-and-ucl-present-new-minimal-residual-disease-surveillance-data-from-their-collaboration-at-2020-aacr-virtual-annual-meeting/

ArcherDX and UCL Present New Minimal Residual Disease Surveillance Data from their Collaboration at 2020 AACR Virtual Annual Meeting First presentation of the data utilizing […]
ArcherDX and Premier Inc. Partner to Deliver Personalized Genomic Testing to Patients https://archerdx.com/archerdx-and-premier-inc-partner-to-deliver-personalized-genomic-testing-to-patients/

ArcherDX and Premier Inc. Partner to Deliver Personalized Genomic Testing to Patients STRATAFIDE™ Proprietary Test Designed to Enable Community Hospitals to Rapidly Deliver Accurate and […]
Letter from Chief Executive Officer and Co-founder, Jason Myers https://archerdx.com/letter-from-chief-executive-officer-and-co-founder-jason-myers/

Letter from Chief Executive Officer and Co-founder, Jason Myers April 17, 2020 Over the course of the last several weeks, our lives have been disrupted […]